Anders Karlén of Uppsala University: Featured Speaker at World Anti-Microbial Resistance Congress

Anders Karlén, Professor in Computer-aided drug design, Uppsala University, Sweden, is presently the overall medicinal chemistry project leader for drug discovery efforts currently directed at five different anti-bacterial targets at Uppsala University. Several of these projects have been run within EU framework 6 and 7 programmes. Since February 2014 he is the Leader of the Managing Entity and co-coordinator of the …

[WHITEPAPER] MDRO Trends Throughout Intermountain Healthcare System

 MDRO Trends Throughout Intermountain Healthcare System  courtesy of OpGen This whitepaper discusses a study conducted by Intermountain Healthcare System and Enterprise Analysis Corporation (EAC) with support from OpGen that examined the trends in MDROs (multidrug resistant organisms) over the 8 year period of 2008-2015. The paper discusses the objectives of the study, which was initiated in December 2015 and concluded …

[WHITEPAPER] Quantitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 1

Quanitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 1 courtesy of PSI CRO The first in a two-part article, this whitepaper discusses the challenges and best practices involved in achieving ideal outcomes in quantitative urine culture studies. Download the whitepaper now to learn more about: urine specimen stability quantitative urine culture contamination rates …and more ! …

Larry Tsai of Tetraphase Pharmaceuticals: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Larry W. Tsai has been Vice President of Clinical Development of Tetraphase Pharmaceuticals since 2015. In this role he establishes clinical development plans and oversees the clinical development of drug candidates from first-in-man through late-stage clinical trials. He joined Tetraphase in 2014 as senior medical director. Prior to Tetraphase, he worked at Aeris Therapeutics where he served most recently …

Qualified Infectious Disease Product Designation and Unmet Need Development Programs

“Qualified Infectious Disease Product Designation and Unmet Need Development Programs”

Sumati Nambiar, MD MPH, Director of the Division of Anti-Infective Products, FDA joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘qualified infectious disease product designation and unmet need development programs’ . In this presentation, learn in-depth information regarding Qualified Infectious Disease Product (QIDP) designation. Download the presentation to understand more about: Criteria and incentives for QIDP designation …

FDA Regulation of Clinical Microbiology and AST Diagnostic Devices

“FDA Regulation of Clinical Microbiology and AST Diagnostic Devices”

Ribhi Shawar of FDA joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘FDA regulation of clinical microbiology and AST diagnostic devices’ . In this presentation, learn about some examples of challenges in data presentation/analysis as well as scientific and regulatory process understanding. Download the presentation to understand more about: Progress in microbial diagnostics, including AMR Highlights of …

World Anti-Microbial Resistance Congress

Rosemarie Aurigemma of NIAID, NIH: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Rosemarie Aurigemma is Chief of the Drug Development Section in the Office of Biodefense Research Resources and Translational Research at NIAID, NIH, where she directs the advancement of new therapies for existing and emerging infectious diseases important to public health such as influenza, antibiotic resistant infections, and dengue fever, as well as for infectious bioterrorism agents, such as anthrax, …